

Supporting Information

DOI: 10.1039/x0xx00000x

Hybrid Red Blood Cell Membrane Coated Porous Silicon Nanoparticles Functionalized with Cancer Antigen Induce Depletion of T Cells

Antti Rahikkala,^{*a} Flavia Fontana,^a Tomás Bauleth-Ramos,^{b,c,d} Alexandra Correia,^a Marianna Kemell,^e Jani Seitsonen,^f Ermei Mäkilä,^g
Bruno Sarmiento,^h Jarno Salonen,^g Janne Ruokolainen,^f Jouni Hirvonen,^a and Hélder A. Santos^{*a,i}

- ^a. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki (Finland).
- ^b. Instituto de Investigação e Inovação em Saúde (I3S), University of Porto, Rua Alfredo Allen, 208, 4200-135, Porto (Portugal).
- ^c. Instituto de Engenharia Biomédica (INEB), University of Porto, Rua Alfredo Allen, 208 4200-135, Porto (Portugal).
- ^d. Instituto Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Rua Jorge Viterbo 228, 4150-180, Porto (Portugal)
- ^e. Department of Chemistry, University of Helsinki, FI-00014, Helsinki (Finland)
- ^f. Nanomicroscopy Center, Aalto University, FI-02150, Espoo (Finland)
- ^g. Laboratory of Industrial Physics, Department of Physics, University of Turku, FI-20014, Turku (Finland)
- ^h. CESP, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde & Instituto Universitário de Ciências da Saúde, 4585-116 Gandra, Portugal
- ⁱ. Helsinki Institute of Life Science (HiLIFE), University of Helsinki, FI-00014, Helsinki (Finland)

*Corresponding authors:

antti.rahikkala@helsinki.fi

helder.santos@helsinki.fi

Conjugation efficiencies: The conjugation efficiency of TRP-2 to PDMS-PMOXA and PDMS-PMOXA-TRP2 to RBC ghosts was studied by measuring fluorescence intensity (**Figure S1**). TRP-2, functionalized with fluorescein isothiocyanate (FITC), was dissolved in EtOH at 10, 50, 100, 150, 200, 250, and 300 $\mu\text{g}/\text{mL}$ to prepare the calibration samples. 100 μL triplicates of each calibration sample were inserted into a 96 well plate. Subsequently, PDMS-PMOXA-TRP2 and RBC-p-TRP2 samples were otherwise prepared as described in Materials and methods, however, these samples were ultracentrifuged after which phosphate buffered saline (PBS) was replaced with similar amount of EtOH. The PDMS-PMOXA-TRP2 and RBC-p-TRP2, each containing 5 $\mu\text{g}/\text{mL}$ TRP-2, were inserted into the wellplate in triplicates of 100 μL . Furthermore, a sample of RBC ghosts in EtOH was inserted into the wellplate to measure their autofluorescence. The fluorescence was measured using a microplate reader (Varioskan LUX, ThermoFisher Scientific, Waltham, MA, USA) with excitation wavelength at 492 nm and recording emission at 515 nm. RBC ghosts had autofluorescence corresponding to $1.0 \pm 0.2 \mu\text{g mL}^{-1}$ of TRP-2. PDMS-PMOXA-TRP and RBC-p-TRP had fluorescence corresponding to 15.7 ± 0.8 and $24.3 \pm 0.5 \mu\text{g mL}^{-1}$ TRP2, respectively. In practice, both the PDMS-PMOXA-TRP2 and RBC-PDMS-PDMS-PMOXA-TRP2 have TRP2 content that corresponds to $5 \mu\text{g mL}^{-1}$ TRP2. However, the fluorescence is amplified by the microenvironment of the PDMS-*b*-PMOXA micelles and RBC PDMS-PMOXA-TRP2 ghosts. This experiment was not performed on the samples with encapsulated UnTHCPSi due to their solid form that interferes the light path in the fluorescence measurement.




Figure S1. The addition efficiency of TRP2 to PDMS-PMOXA and PDMS-PMOXA-TRP2 to RBC ghosts was studied by measuring fluorescence intensity. The calibration curve equation is $\text{Fluorescence} = (0.49 \text{ mL } \mu\text{g}^{-1} \pm 0.01 \text{ mL } \mu\text{g}^{-1}) \times \text{TRP2 concentration} + (1.34 \pm 2.30)$. The conjugation of TRP2 to PDMS-*b*-PMOXA was performed by EDC-NHS click chemistry. The product was purified by centrifuging.




Figure S2. The stability of UnPSi-TRP@RBC and UnPSi@RBC-PDMS-PMOXA-TRP2 was studied using a zetasizer (Zetasizer Nano, Malvern PANalytical Ltd, Malvern, UK). Nanoparticle samples of 1 mL volume and 50 $\mu\text{g mL}^{-1}$ concentration were dispersed in triplicates in pH 7.4 PBS containing 5.4% glucose. The sample vials were maintained under constant stirring at 37 °C temperature. At set time points (0 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h), 100 μL samples were withdrawn and diluted to 1 mL in pH 7.4 PBS containing 5.4% glucose. The size and PDI of the diluted samples were then analyzed using the zetasizer.




Figure S3. a) Cryo-electron micrograph of a nanosized RBC ghost, imaged at 120 kV acceleration voltage in a bright-field mode. b) Cryo-electron micrograph of UnPSi@RBC-p-TRP2 (upper particle) and an empty RBC-p-TRP2 ghost (lower particle), imaged at acceleration voltage of 120 kV in a bright-field mode.




Figure S4. Gating strategy used in the flow cytometry experiments, showing as examples the gating in the a) PBMC control sample and b) Un@autoRBC-p-TRP2. Prior to measuring the PBMC in the flow cytometer, they were labeled with CellTrace Violet, anti-human CD3/4/8, and 7-AAD viability dye.




Figure S5. Lymphocyte depletion showing all the measured samples. TRP-2 and PDMS-*b*-PMOXA-TRP-2 had no effect on the percentage of T cells.




Figure S6. The changes in the number of CD4⁺- and CD8⁺ T cells, compared to the control. The graph is normalized to show the change compared to the expression of CD4⁺ and CD8⁺ T cells in untreated PBMC samples, where CD3⁺ CD4⁺ T cells consisted of 70% ± 1% and CD3⁺ CD8⁺ of 24% ± 1% of all the CD3⁺ PBMCs. N = 3 for all experiments; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005.